Market revenue in 2023 | USD 121.3 million |
Market revenue in 2030 | USD 257.1 million |
Growth rate | 11.3% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the India mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
India’s biotechnology sector is witnessing rapid growth, with increasing investments in R&D and capacity/facility expansion, among others. The country also has a large pool of skilled scientists, researchers, and professionals in biotechnology & pharmaceuticals.
This skilled workforce is appealing to companies looking for outsourcing partners. Furthermore, India’s cost structure and relatively lower labor costs compared to Western countries make it an attractive destination for outsourcing mRNA development and manufacturing. This cost advantage is especially significant for startups and small- to medium-sized biotech firms.
For instance, in October 2022, Yapan Bio— an Indian CDMO—inaugurated a new process development facility in Hyderabad, India, thus expanding its capabilities in end-to-end development and manufacturing of RNA, DNA, and gene therapy products.
Horizon Databook provides a detailed overview of country-level data and insights on the India mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into India mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account